Coloplast A/S (OTCMKTS:CLPBY) Upgraded at Barclays

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by investment analysts at Barclays from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday, Zacks reports.

Coloplast A/S Price Performance

OTCMKTS:CLPBY opened at $7.80 on Tuesday. The company has a market cap of $17.59 billion, a P/E ratio of 37.16, a P/E/G ratio of 2.85 and a beta of 0.10. The firm’s fifty day moving average price is $6.85 and its two-hundred day moving average price is $6.79. Coloplast A/S has a one year low of $5.64 and a one year high of $9.57. The company has a debt-to-equity ratio of 1.51, a current ratio of 1.56 and a quick ratio of 0.94.

Coloplast A/S (OTCMKTS:CLPBY) last posted its earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.09. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Coloplast A/S had a net margin of 10.57% and a return on equity of 42.25%. Equities analysts expect that Coloplast A/S will post 0.40 earnings per share for the current year.

About Coloplast A/S

Coloplast A/S is a Denmark-based medical technology company that develops, manufactures and markets products designed to help people manage intimate health conditions. Its core businesses include ostomy care, continence care, wound and skin care, and interventional urology. The company’s products are used by patients and healthcare professionals in hospitals, clinics and home-care settings.

Coloplast was founded in Denmark in 1957 after nurse Elise Sørensen helped develop an adhesive ostomy bag for her sister, who had undergone surgery.